Tag Archives: advice

They take offense, but their food makes me sick | Instant News

Dear Amy: I am currently grappling with several serious food allergies. A laboratory blood test recently revealed an autoimmune disorder. I’m scheduled to see a rheumatologist in two months.

Amy Dickinson

My body was thrown into a vicious circle for weeks after consuming allergy-inducing foods.

So, what should I do when I’m hanging out with friends or family for dinner and they’re trying to make a special meal for me? I don’t want to risk even trying this food because of past experiences with bad reactions.

Recently, a host assured me that all the ingredients were safe for me, only to find out later that they had greased the pan with margarine, which triggered my allergy.

They just don’t understand how I have to pay for even a small meal for the next three weeks, but they feel bad because I can’t eat what they eat, and they love food so much they want to share it with me.

What I prefer to do is bring my own food, but of course people are so offended or feel so sorry for me that they will try to make something just for me.


image source

Octapharma AG: Final data from the published NuProtect study on the immunogenicity of Nuwiq® in previously untreated patients with severe hemophilia A | Instant News

LAUGH, Switzerland, 22 February 2021 / PRNewswire / –Octapharma AG today announced the final results of the NuProtect study on Nuwiq immunogenicity® on previously untreated patients (PUP) with severe hemophilia A has been published in leading medical journals Thrombosis and Hemostasis (Liesner RJ et al. “Simoctocog Alfa (Nuwiq®) in a Previously Untreated Patient with Severe Hemophilia A: The End Result of the NuProtect Study ” https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1722623).

The NuProtect Study (NCT01712438; EudraCT 2012-002554-23) is a prospective, multinational, open-label, uncontrolled phase III study initiated in March 2013 to assess the immunogenicity, efficacy and safety of Nuwiq®. The study recruited patients of all ages and ethnicities at 38 locations in 17 countries and followed patients for 100 days or up to 5 years. With a enrollment of 110 patients, the NuProtect study is the largest clinical study to investigate a single product in true PUPs.

Of the 105 PUPs that could be evaluated with severe hemophilia A who received Nuwiq® for prevention and treatment of bleeding:

  • 16.2% (17/105) of patients developed high titer inhibitors
  • 10.5% (11/105) of patients developed low titer inhibitors, five of which were transient
  • 26.7% (28/105) of patients developed any inhibitor

The NuProtect study shows that there is a low risk of inhibitor development in PUPs starting treatment with Nuwiq®, “comments Dr. Ri Liesner, NuProtect study research coordinator and clinician at Great Ormond Street Hospital for Children at London, England. “This data shows Nuwiq® may be an attractive option for people recently diagnosed with severe hemophilia A, who are children and constitute a subset of susceptible patients.. “

The development of inhibitors into replacement factor VIII (FVIII) is of concern to doctors, as well as for patients and their families, especially when they first start treatment. Inhibitors make FVIII therapy ineffective and limit treatment options.

These data complement the wealth of clinical experience in hemophilia A patients receiving Nuwiq® for the treatment and prevention of bleeding.

“Nuwiq® developed in human cell lines with the aim of minimizing the risk of inhibitors in PUPs,said Larisa Belyanskaya, Head of Hematology, MOM Octapharma. “We are delighted to share this positive data, which reflects this goal and which we hope will contribute to addressing this major treatment challenge. ”

We know that hemophilia A patients face life-long treatment decisions, “commented Olaf Walter, Board Member at Octapharma. “This data highlights Nuwiq’s potential® to reassure PUP and their families when they start treatment. This publication brings us closer to Octapharma’s goal of enabling all patients to lead healthy lives. “

Earlier this year the FDA approved the inclusion of immunogenicity data from the NuProtect study at Nuwiq.® Prescribing Information. Further publication of another analysis of the NuProtect study is planned.

Professor Anthony Chan, co-author of the publication and Professor of Paediatrics at McMaster University, Canada, said: “Congratulations and thanks to Octapharma for developing Nuwiq, sponsoring trials and providing excellent therapy for hemophilia A.

Octapharma would also like to thank all participating centers, as well as their patients and caregivers, for their contributions to this research.

About Nuwiq®

Nuwiq® (simoctocog alpha) is a 4th generation recombinant factor VIII (rFVIII) protein, produced in human cell lines without chemical modification or fusion with other proteins.1. It is cultivated without additives of human or animal origin, without antigenic non-human protein epitopes and has a high affinity for von Willebrand factor.1. Nuwiq® treatment was assessed in seven comprehensive clinical trials that included 201 previously treated patients (PTP; 190 people) with severe hemophilia A, including 59 children.1. Nuwiq® available in 250 IU, 500 IU, 1000 IU, 2000 IU, 2500 IU, 3000 IU and 4000 IU presentations2. Nuwiq® approved for use in the treatment and prophylaxis of bleeding in patients with hemophilia A (congenital FVIII deficiency) in all age groups2.

1. Lissitchkov T et al. There is Adv Hematol 2019; 10: 2040620719858471.
2. Nuwiq® Summary of Product Characteristics.

About Hemophilia A

Hemophilia A is an X-linked hereditary bleeding disorder caused by factor VIII (FVIII) deficiency which, if left untreated, can lead to bleeding in the muscles and joints and consequently to arthropathy and severe morbidity. This disorder affects about one in every 10,000 men worldwide. Prophylaxis with FVIII replacement therapy reduces the number of bleeding episodes and the risk of permanent joint damage.

About Octapharma

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein producers in the world, developing and producing human proteins from human plasma and human cell lines.

Octapharma employs more than 9,000 people worldwide to support patient care in 118 countries with products in three therapeutic areas: Hematology, Immunotherapy and Critical Care.

Octapharma has seven R&D locations and six state-of-the-art manufacturing facilities at Austria, France, German, Mexico and Sweden, and operates more than 160 plasma donation centers Europe and United States of America.

Logo: https://mma.prnewswire.com/media/1442016/Octapharma_Logo.jpg

Cision View original content for multimedia downloads:http://www.prnewswire.com/news-releases/octapharma-ag-final-data-from-the-nuprotect-study-published-on-the-immunogenicity-of-nuwiq-in-previously-untreated-patients- with-hemophilia-heavy-a-301232601.html

SOURCE Octapharma AG


image source

GCPS tells students and staff to self-quarantine after international travel as county cases continue to decline | News | Instant News

Students and employees at Gwinnett County public schools will be required to stay home for at least a week if they leave the country for vacation. The school system recently announced that it will follow CDC guidelines on relations with international travelers. Federal agency guidelines state that a person traveling overseas must be tested for COVID-19 three to five days after returning to the United States and remain in quarantine. Even if the person is negative, they still need to self-quarantine after returning. In other words, students and staff traveling outside of the United States will not be able to return to school or work for at least seven days after their return to the United States, ”district officials said in a flyer on the school system’s website. district officials say students and staff should be quarantined for “at least” seven days because that’s only the period of time for people who test negative. If a student or staff member returns from an international trip, but refuses to be tested, then they should be quarantined for 10 days. They should also be on the lookout for symptoms and get tested immediately if symptoms of COVID start to appear.If a student or staff member is tested and the results are positive, they should follow current health guidelines. for current cases of the disease, according to district officials. CDC’s full advice for international travelers can be found at bit.ly/2NL1Rv0. Success! An email has been sent with a link to confirm the listing. Fault! There was an error processing your request. Gwinnett County Public Schools reported on Friday that there were 232 new cases of COVID-19 reported to the school system on Thursday. This includes 188 students and 44 staff. The district reported that there were a total of 199 active positive COVID-19 cases, 156 active suspected cases and 1,345 close contacts on Friday. Gwinnett County, which is the second largest Georgia’s most populous county, continues to lead overall two-week new cases with 3,224 reported on Friday, but its two-week incidence rate continues to decline. The county’s two-week incidence rate was at 332 cases per 100,000 inhabitants on Friday. a total of 78,774 cases, 857 confirmed deaths, 58 probable deaths, and 4,906 hospitalizations from COVID-19 since March 2020 Statewide, Georgia has recorded a total of 34,864 new cases over two weeks, with a two-week incidence rate of 322 cases per 100,000 population. Georgia has now reported 800,959 cases of COVID-19 since March, with an incidence rate of 7,393 cases per 100,000 population. There have been 14,530 confirmed deaths and 2,080 probable deaths from the disease. There have also been 54,434 hospitalizations and 8,898 intensive care admissions in the state due to COVID-19. .

image source

SHC is annoyed at the absence of FBR advice on tax-related matters | Instant News

KARACHI: The Sindh High Court (SHC) has expressed disappointment over the continued absence of Federal Revenue Council advisers and representatives on several tax-related matters before courts where a residence order operates against the FBR for more than six months.

While listening to an identical petition regarding amendments to income tax regulations and the unilateral withdrawal of tax incentives, a division bench of the high court, presided over by Judge Mohammad Junaid Ghaffar, took a serious exception to the FBR board which has not appeared on the pending petition since 2019.

The judge observed that although the argument was submitted by the applicant’s attorney on 19 November 2020, the matter has been postponed since then and no one on behalf of FBR has appeared to process the case.

The SHC observed that one deputy interior income commissioner had appeared before the court and, when confronted, he was not in a position to continue or assist the court in any way and asked for further time. The court expressed disappointment over the department’s actions.

The high court observed that judges have been set up to decide taxation issues, where stay orders operate for more than six months but despite repeated notifications, in most of the cases it was FBR that caused delays and was a hindrance to the early discharge of such cases.

Bench recalls that in the previous Customs reference, non-representative and non-assistance by the FBR advisor has shown and it was observed that in a number of cases related to the Customs department, tax collectors (prevention) and Ports

Qasim’s representatives and advisers despite being given notice always chose not to attend and defend the matter. SHC observed that this was a sad situation as far as assistance from FBR was concerned as there was a legal wing and an independent department within the Council. Income but still their behavior before the courts is pathetic.

The high court observed that there was no positive effort by the FBR department and directed the office to send a copy of the order to the chairman of FBR as well as inland revenue (operations) and member (legal) member, FBR, for information on the circumstances.

SHC said that there are many similar things that can be heard and decided quickly; therefore, the court was forced to order the office to note that this matter should not be treated as partially heard and will be corrected at a later date. The court also ordered an interim order, if any, to continue until the next trial date.


image source

Joint Statement by Foreign Ministers of France, Germany, Italy, Britain and the United States – Rocket attack in Erbil (16 February 2021) | Instant News

We, the foreign ministers of France, Germany, Italy, Great Britain and the United States strongly condemn the February 15 rocket attack on Iraq’s Kurdistan Region. We extend our condolences to the victims, their families and the Iraqi people. Together, our governments will support the Government of Iraq’s investigation into the attacks with a view to holding those responsible to account. We are united in our view that attacks on the US and Coalition personnel and facilities will not be tolerated.


image source